Evaluation of the Safety of Lead Compounds for Allergic Asthma [ 2017 - ]

Research Grant

Researchers: A/Pr Mark Smythe (Principal investigator) ,  A/Pr Simon Phipps

Brief description Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.

Funding Amount $310,568.00

Funding Scheme Development Grants

Notes Development Grant